Literature DB >> 12169636

Different telomere damage signaling pathways in human and mouse cells.

Agata Smogorzewska1, Titia de Lange.   

Abstract

Programmed telomere shortening in human somatic cells is thought to act as a tumor suppressor pathway, limiting the replicative potential of developing tumor cells. Critically short human telomeres induce senescence either by activating p53 or by inducing the p16/RB pathway, and suppression of both pathways is required to suppress senescence of aged human cells. Here we report that removal of TRF2 from human telomeres and the ensuing de-protection of chromosome ends induced immediate premature senescence. Although the telomeric tracts remained intact, the TRF2(DeltaBDeltaM)-induced premature senescence was indistinguishable from replicative senescence and could be mediated by either the p53 or the p16/RB pathway. Telomere de-protection also induced a growth arrest and senescent morphology in mouse cells. However, in this setting the loss of p53 function was sufficient to completely abrogate the arrest, indicating that the p16/RB response to telomere dysfunction is not active in mouse cells. These findings reveal a fundamental difference in telomere damage signaling in human and mouse cells that bears on the use of mouse models for the telomere tumor suppressor pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12169636      PMCID: PMC126171          DOI: 10.1093/emboj/cdf433

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  54 in total

1.  A mutant with a defect in telomere elongation leads to senescence in yeast.

Authors:  V Lundblad; J W Szostak
Journal:  Cell       Date:  1989-05-19       Impact factor: 41.582

2.  Specific chromosome aberrations in senescent fibroblast cell lines derived from human embryos.

Authors:  P A Benn
Journal:  Am J Hum Genet       Date:  1976-09       Impact factor: 11.025

Review 3.  A survey of telomerase activity in human cancer.

Authors:  J W Shay; S Bacchetti
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

4.  Viable deletions of a telomere from a Drosophila chromosome.

Authors:  R W Levis
Journal:  Cell       Date:  1989-08-25       Impact factor: 41.582

5.  Quantitation of the frequency of immortalization of normal human diploid fibroblasts by SV40 large T-antigen.

Authors:  J W Shay; W E Wright
Journal:  Exp Cell Res       Date:  1989-09       Impact factor: 3.905

6.  A biomarker that identifies senescent human cells in culture and in aging skin in vivo.

Authors:  G P Dimri; X Lee; G Basile; M Acosta; G Scott; C Roskelley; E E Medrano; M Linskens; I Rubelj; O Pereira-Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-26       Impact factor: 11.205

7.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

8.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

9.  Structure and variability of human chromosome ends.

Authors:  T de Lange; L Shiue; R M Myers; D R Cox; S L Naylor; A M Killery; H E Varmus
Journal:  Mol Cell Biol       Date:  1990-02       Impact factor: 4.272

10.  Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells.

Authors:  T Kiyono; S A Foster; J I Koop; J K McDougall; D A Galloway; A J Klingelhutz
Journal:  Nature       Date:  1998-11-05       Impact factor: 49.962

View more
  145 in total

Review 1.  Telomere architecture.

Authors:  Daniela Rhodes; Louise Fairall; Tomas Simonsson; Robert Court; Lynda Chapman
Journal:  EMBO Rep       Date:  2002-12       Impact factor: 8.807

Review 2.  Telomere structure, function and maintenance in Arabidopsis.

Authors:  Karel Riha; Dorothy E Shippen
Journal:  Chromosome Res       Date:  2003       Impact factor: 5.239

Review 3.  When cells get stressed: an integrative view of cellular senescence.

Authors:  Ittai Ben-Porath; Robert A Weinberg
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

4.  Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells.

Authors:  A Satyanarayana; S U Wiemann; J Buer; J Lauber; K E J Dittmar; T Wüstefeld; M A Blasco; M P Manns; K L Rudolph
Journal:  EMBO J       Date:  2003-08-01       Impact factor: 11.598

5.  Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling.

Authors:  A Satyanarayana; R A Greenberg; S Schaetzlein; J Buer; K Masutomi; W C Hahn; S Zimmermann; U Martens; M P Manns; K L Rudolph
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

6.  Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7.

Authors:  H R McMurray; D J McCance
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 7.  Assessing cell and organ senescence biomarkers.

Authors:  Bruno Bernardes de Jesus; Maria A Blasco
Journal:  Circ Res       Date:  2012-06-22       Impact factor: 17.367

8.  Increased p53 activity does not accelerate telomere-driven ageing.

Authors:  Isabel García-Cao; Marta García-Cao; Antonia Tomás-Loba; Juan Martín-Caballero; Juana M Flores; Peter Klatt; María A Blasco; Manuel Serrano
Journal:  EMBO Rep       Date:  2006-03-31       Impact factor: 8.807

9.  No attenuation of the ATM-dependent DNA damage response in murine telomerase-deficient cells.

Authors:  Natalie Erdmann; Lea A Harrington
Journal:  DNA Repair (Amst)       Date:  2008-12-25

10.  Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis.

Authors:  Ram P Naikawadi; Supparerk Disayabutr; Benat Mallavia; Matthew L Donne; Gary Green; Janet L La; Jason R Rock; Mark R Looney; Paul J Wolters
Journal:  JCI Insight       Date:  2016-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.